PureTech Health PLC
PRTC20.000USD
+0.911+4.77%
Market hours （ET）Quotes delayed by 15 min
4.79BMarket Cap
--P/E TTM
More Details of PureTech Health PLC Company
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
Company Info
Ticker SymbolPRTC
Company namePureTech Health PLC
IPO dateJun 19, 2015
CEOMr. Robert (Rob) Lyne
Number of employees56
Security typeOrdinary Share
Fiscal year-endJun 19
Address6 Tide Street
CityBOSTON
Stock exchangeLondon Stock Exchange
CountryUnited States of America
Postal code02210
Phone16174822333
Websitehttps://puretechhealth.com/
Ticker SymbolPRTC
IPO dateJun 19, 2015
CEOMr. Robert (Rob) Lyne
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Mr. Robert (Rob) Lyne
Mr. Robert (Rob) Lyne
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Dr. Charles H. Sherwood, Ph.D.
Dr. Charles H. Sherwood, Ph.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Jun 2
Updated: Mon, Jun 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Birch Hill Investment Advisors LLC
1.01%
Millennium Management LLC
0.19%
Pentwater Capital Management LP
0.14%
Portolan Capital Management, L.L.C.
0.05%
Other
98.62%
Shareholders
Shareholders
Proportion
Birch Hill Investment Advisors LLC
1.01%
Millennium Management LLC
0.19%
Pentwater Capital Management LP
0.14%
Portolan Capital Management, L.L.C.
0.05%
Other
98.62%
Shareholder Types
Shareholders
Proportion
Investment Advisor
1.26%
Hedge Fund
0.33%
Investment Advisor/Hedge Fund
0.05%
Other
98.36%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
15
335.52K
1.39%
-63.86K
2025Q1
14
393.56K
1.64%
-4.75K
2024Q4
14
374.87K
1.56%
+317.90K
2024Q3
13
30.04K
0.13%
-317.21K
2024Q2
12
323.23K
1.35%
+280.87K
2024Q1
9
25.15K
0.09%
-3.71K
2023Q4
10
11.40K
0.04%
-82.93K
2023Q3
12
84.27K
0.31%
-16.31K
2023Q2
11
83.51K
0.30%
-16.43K
2023Q1
13
82.93K
0.30%
-317.41K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Birch Hill Investment Advisors LLC
302.00K
1.25%
--
--
Mar 31, 2025
Millennium Management LLC
44.91K
0.19%
-353.00
-0.78%
Mar 31, 2025
Pentwater Capital Management LP
33.56K
0.14%
+9.45K
+39.19%
Mar 31, 2025
Portolan Capital Management, L.L.C.
11.88K
0.05%
+11.88K
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.28K
0.01%
--
--
May 31, 2025
Geode Capital Management, L.L.C.
770.00
0%
--
--
May 31, 2025
Dimensional Fund Advisors, L.P.
316.00
0%
-208.00
-39.69%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
100.00
0%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
20.00
0%
-1.88K
-98.95%
Mar 31, 2025
Dimensional Fund Advisors, Ltd.
--
0%
-196.00
-100.00%
Jan 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
